[Progress is nescessary! New antidementia drugs].
Nemec
Karin
K
Institut für Pharmazeutische Chemie Marie-Curie-Str. 9, 60439 Frankfurt. Schubert.Zsilavecz@pharmchem.uni-frankfurt.de
Schubert-Zsilavecz
Manfred
M
D000368:Aged; D000595:Amino Acid Sequence; D062365:Aminobenzoates; D016229:Amyloid beta-Peptides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007042:Hypoxanthines; D008969:Molecular Sequence Data; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D014612:Vaccines / Q000627:therapeutic use
C437846:AN-1792; D062365:Aminobenzoates; D016229:Amyloid beta-Peptides; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007042:Hypoxanthines; D011619:Psychotropic Drugs; D011687:Purines; D014612:Vaccines; C086241:4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid